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OBJECTIVES We sought to assess the effect of ramipril on left ventricular (LV) volumes, and the clinical
significance thereof, in patients with moderate LV dysfunction and no clinical heart failure
undergoing invasive revascularization for chronic stable angina.
BACKGROUND It is unsettled whether treatment with an angiotensin-converting enzyme inhibitor has an
impact on LV volumes in this patient group, and, if so, whether this is associated with the
clinical outcome.
METHODS A total of 133 patients with a left ventricular ejection fraction (LVEF) between 0.30 and 0.50
and no clinical heart failure undergoing invasive revascularization for chronic stable angina
were randomized to receive ramipril 10 mg once daily or placebo and were followed for a
median of 33 months with echocardiography at baseline and 3, 12 and 24 months
postoperatively.
RESULTS Repeated measures analysis of all time points showed that ramipril significantly reduced the
end-diastolic volume index (EDVI) (p 5 0.032) and end-systolic volume index (ESVI) (p 5
0.006) as compared with placebo. Ramipril also reduced the incidence of the triple composite
end point of cardiac death, acute myocardial infarction or development of heart failure (p 5
0.046). Cox regression analysis, controlling for baseline LVEF and assignment to ramipril,
revealed: 1) that increases in EDVI and ESVI up to three months predicted an increasing risk
of a future adverse clinical outcome; and 2) that the benefit with ramipril on clinical outcome
was partly dependent on a reduction in LV volumes.
CONCLUSIONS Even in this patient group, LV dilation may supervene and lead to an adverse clinical
outcome. Ramipril reduces the postoperative increase in LV volumes and may thereby
improve clinical outcome. (J Am Coll Cardiol 2001;37:1214–20) © 2001 by the American
College of Cardiology
In patients with ischemic heart disease, left ventricular (LV)
volume and left ventricular ejection fraction (LVEF) are
important predictors of prognosis (1–3). Thus, interven-
tions that may influence these variables may alter the clinical
course. After invasive revascularization, LV volume and
LVEF may change due to a recovery of stunned or hiber-
nating myocardium (4–6), due to periprocedural ischemia
and the progressive nature of the disease (5) or due to a loss
of pericardial strain after pericardiotomy (7).
Angiotensin-converting enzyme (ACE) inhibitor treat-
ment has been shown to attenuate LV dilation and decrease
in LVEF after acute myocardial infarction (AMI) in pa-
tients with LV dysfunction (8–12), and at least part of the
clinical benefit with ACE inhibitor treatment has been
attributed to this mechanism (9–11). In the Angiotensin-
converting enzyme inhibition Post REvascularization Study
(APRES) (13), which included patients with moderately
impaired LV function and no clinical heart failure under-
going invasive revascularization for chronic stable angina
pectoris, we found that ramipril, an ACE inhibitor, im-
proved the clinical outcome with respect to cardiac death,
AMI and development of heart failure.
Because the beneficial effects of ACE inhibitor treatment
on LV volume and LVEF have primarily been described in
patients with severe LV dysfunction (9–11) and within the
first month(s) after an AMI (8,9,12), and because invasive
revascularization may alter LV volume and LVEF (4–7) per
se, it remains to be elucidated whether the beneficial effects
of ACE inhibitor treatment on LV volume and LVEF may
apply to patients with moderately impaired LV dysfunction
undergoing invasive revascularization for chronic angina
pectoris, and, if so, whether this effect may be associated
with a beneficial effect on clinical outcome.
The aim of the present study was to assess, in this patient
group, whether treatment with ramipril initiated early after
invasive revascularization improves the outcome with re-
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spect to LV volume and LVEF, whether the serial changes
in these provide independent predictive information and
whether the impact of ramipril on LV volume and LVEF is
associated with the clinical outcome.
METHODS
Patients. Included in this study were patients in APRES
(13) in whom a baseline and at least one postoperative
echocardiogram was obtained. In short, after uncomplicated
invasive revascularization with coronary artery bypass graft
surgery (CABG) or percutaneous transluminal balloon an-
gioplasty (PTCA) for chronic stable angina pectoris, pa-
tients with no clinical heart failure, no need for diuretics for
heart failure and LVEF between 0.30 and 0.50, as deter-
mined by ventriculography or echocardiography, were ran-
domized to receive ramipril 10 mg once daily or placebo and
were followed for a median of 33 months. The study was
approved by the local Ethics Committee and the National
Board of Health, and all patients gave written, informed
consent.
Outcome measures. The main outcome measures were the
changes from baseline to 3, 12 and 24 months postopera-
tively in left ventricular end-diastolic volume index (EDVI),
end-systolic volume index (ESVI) and LVEF, as deter-
mined by echocardiography. The LVEF was derived from
(EDVI 2 ESVI/EDVI). Clinical end points were the triple
composite end point of cardiac death, AMI or development
of heart failure, and cardiac death alone (13).
Echocardiographic methods and reproducibility. Echo-
cardiography was performed at baseline and at 3, 12 and 24
months postoperatively. Patients undergoing CABG had
baseline echocardiography performed before the operation,
whereas patients undergoing PTCA had echocardiography
performed after the procedure but before randomization,
because of a policy of ad hoc PTCA during some of the
study period. Apical two- and four-chamber recordings
were obtained and digitized on-line and stored on optical
discs. All recordings and analyses were done by a single
observer. To prevent bias in the analysis of serial changes,
recordings from separate occasions were arranged by patient
side by side in a quadscreen format and in a random manner
with respect to recording dates. All recordings were ana-
lyzed in a blinded manner with regard to the examination
date, patient data and treatment code. Endocardial borders
were traced manually in the two- and four-chamber apical
views at end-diastole (defined as the frame at the beginning
of the QRS complex) and at end-systole (defined as the
frame before the early opening of the mitral valve). Biplane
volumes were calculated by the disc summation method
(modified Simpson’s rule) and indexed according to body
surface area at baseline. For statistical analyses, the mean
results of three separate endocardial tracings and calcula-
tions were used. In a random sample of 50 patients, the
biplane volume analysis was repeated. The repeatability
coefficients (14) (i.e., two standard deviations [SD] of the
difference of repeated analyses for DEDVI, DESVI and
DLVEF [derived from ESVI and EDVI]) were 9.5 ml/m2,
9.7 ml/m2 and 0.13, respectively.
To provide an independent baseline LVEF, a nine-
segment wall motion index (WMI) was determined in a
separate session. This method has previously been evalu-
ated, and an estimate of LVEF can be derived by multiply-
ing the WMI by 0.3 (15). The mean 6 SD difference
between LVEF derived from the biplane volumes and
LVEF derived from WMI and ventriculography was
20.03 6 0.08 and 20.05 6 0.09, respectively.
Statistics. The significance of a treatment effect (ramipril
group vs. placebo group) on EDVI, ESVI and LVEF was
determined by repeated measures analysis of covariance after
adjusting for baseline values, as described by Frison and
Pocock (16). The interaction of baseline variables was
determined by adding these as covariates. As repeated
measures analysis requires measurements of all three post-
operative time points to be available, patients with missing
measures (e.g., death, withdrawal, not followed for 24
months) were assigned an imputed value according to the
mean value of the patients’ postoperative measures. Analyses
using other imputation algorithms, or simply omitting
patients (25% of patients) with a missing measure from the
repeated measures analysis, gave similar results. The per-
centage of imputed values for EDVI, ESVI and LVEF was
10.5%. Significance of change from baseline within treat-
ment groups was tested by the paired t test. Basic intergroup
comparisons were performed by using the unpaired t test for
continuous variables and the chi-square test for categoric
variables.
The predictive information provided by the changes in








CABG 5 coronary artery bypass graft
surgery
CI 5 confidence interval
EDVI 5 end-diastolic volume index
ESVI 5 end-systolic volume index
LV 5 left ventricular
LVEF 5 left ventricular ejection
fraction
PTCA 5 percutaneous transluminal
coronary angioplasty
RR 5 relative risk
SD 5 standard deviation
WMI 5 wall motion index
DEDVI, DESVI, DLVEF 5 increase from baseline in
EDVI and ESVI and
decrease from baseline in
LVEF, respectively
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these as single predictors in a Cox regression proportional
hazards model, with time to clinical event as the dependent
measure. Significant univariate predictors were then added
individually to a Cox regression model, which was con-
structed from baseline variables that were independent
predictors of outcome. Among the continuous variables, age
was entered by decade, baseline WMI ,1.4 (;LVEF
#0.40) and, for the remaining variables, after categorization
into four groups, according to median values and quartiles.
Time dependency of predictor variables was determined and
controlled for if required. Significant changes in EDVI and
ESVI were defined as a postoperative increase larger than
the repeatability coefficient; and a significant change in
LVEF was defined as a decrease larger than the repeatability
coefficient.
The interaction between treatment with ramipril and the
serial changes in LV measures on predictive information
was ascertained by forcing the treatment code into the Cox
regression model, together with the relevant LV measure.
Statistical analyses were performed using Statistica for
Windows, version 5.1 (StatSoft Inc., Tulsa, Oklahoma),
and a significance level of 5% was adapted.
RESULTS
Among the 159 randomized patients (130 after CABG and
29 after PTCA), 133 patients (108 after CABG and 25 after
PTCA) had a baseline and at least one follow-up echocar-
diogram (Table 1). The baseline variables for these patients
were comparable with the baseline variables of the entire
Table 1. Number of Patients in Echocardiographic Study at Each Time Point
No. of Patients at
Time Point Reason for Lacking Echocardiogram
No. of Patients in Each
Treatment Group at Time Point
(Ramipril/Placebo)
Randomized 159 No baseline echocardiogram obtained (n 5 6) 80/79
Insufficient quality of echocardiogram (n 5 7)
Echocardiogram at baseline 146 Died (n 5 3) 73/73
Withdrawal of consent (n 5 6)
Lost to follow-up (n 5 4)
Echocardiogram not obtained (n 5 2)
Echocardiogram at 3 months 131 Died (n 5 4) 66/65
Excluded (endocarditis) (n 5 1)
Withdrawal of consent (n 5 2)
Echocardiogram not obtained (n 5 1)
Echocardiogram at 12 months* 125 Died (n 5 1) 62/63
Not followed for 24 months (n 5 17)
Echocardiogram not obtained (n 5 6)
Echocardiogram at 24 months 101 48/53
*Two patients in whom an echocardiogram was not obtained at three months had an echocardiogram at 12 months. Thus, 133 patients had a baseline and at least one follow-up
echocardiogram.






Mean age (yrs) 61 61
Male gender (%) 91 89
Hypertension (%) 22 29
Diabetes mellitus (%) 6 11
Previous AMI (%) 76 80
Median interval since last AMI (months) 15 16
Electrocardiogram
Anterolateral Q-waves (%) 31 42
Inferoposterior Q-waves (%) 57 50
Left branch bundle block (%) 3 3
Median interval since debut of clinical ischemic heart
disease (months)
41 30
Frequency of single-, double- or triple-vessel disease (%) 15/25/60 15/41/44
Left ventricular ejection fraction (mean/median value)
Ventriculography 0.45/0.45 0.45/0.45
Wall motion index 0.41/0.42 0.43/0.42
Biplane volumes 0.38/0.39 0.40/0.40
End-diastolic volume index (ml/m2, mean/median value) 75.5/76.2 71.6/69.1
End-systolic volume index (ml/m2, mean/median value) 47.3/44.9 43.1/42.4
There were no significant differences between the treatment groups for any baseline variable.
AMI 5 acute myocardial infarction.
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randomized study group (13) (Table 2). The clinical out-
comes of the patients who entered the echocardiographic
study are presented in Table 3.
The mean changes from baseline to 3, 12 and 24 months
postoperatively in EDVI, ESVI and LVEF in the two
treatment groups are depicted in Figures 1 through 3.
Repeated measures analysis of all time points showed
significant differences in the changes in EDVI (p 5 0.032)
and ESVI (p 5 0.006) between the ramipril and placebo
groups, but not for LVEF derived from EDVI and ESVI
(p 5 0.15). These effects resulted from an increase in EDVI
(71.6 to 74.7 ml/m2; p 5 0.07) and ESVI (43.1 to 47.9
ml/m2; p , 0.001) and a decrease in LVEF (0.40 to 0.37;
p , 0.001) in the placebo group; and preserved EDVI (75.5
to 72.8 ml/m2; p 5 0.10), ESVI (47.3 to 46.8 ml/m2; p 5
0.68) and LVEF (0.38 to 0.37; p 5 0.32) in the ramipril
group. The significance of the difference in the treatment
response between the groups was consistent when baseline
WMI ,1.4 (LVEF #0.40), triple-vessel disease, anterolat-
eral Q-waves on the electrocardiogram, use of anti-schemic
drugs and CABG versus PTCA were added as covariates,
individually or together. With all covariates added, p 5
0.021 for DEDVI, p 5 0.003 for DESVI and p 5 0.11 for
DLVEF. The p values for a difference in the mean change
from baseline to the specific time points of 3, 12 and 24
months between treatment groups were 0.005, 0.16 and
0.20 for DEDVI; 0.002, 0.048 and 0.058 for DESVI; and
0.18, 0.059 and 0.086 for DLVEF, respectively.
Univariate regression on triple composite end point of
cardiac death, AMI or development of clinical heart
failure. Increases in EDVI and ESVI and a significant
decrease in LVEF up to 12 months were associated with an
increasing risk of an adverse clinical outcome (Table 4).
Increases in EDVI and ESVI from baseline to three months
and a significant increase in ESVI or a decrease in LVEF up
to 12 months were associated with an increasing risk of a
future adverse outcome (Table 4, right columns).
Multivariate regression analysis on triple composite end
point. As for the main study (13), among the baseline
variables, assignment to ramipril (relative risk [RR] 0.35,
95% confidence interval [CI] 0.12 to 0.98) and WMI ,1.4
(RR 3.23, 95% CI 1.25 to 8.38) were the only independent
predictors of an adverse outcome with respect to the triple
composite end point of cardiac death, AMI or heart failure.
Age, gender, hypertension, diabetes mellitus, use of beta-
blockers, use of calcium antagonists, anterolateral Q-waves
Figure 1. Mean change from baseline (with 95% confidence interval) in left
ventricular end-diastolic volume index in the two treatment groups. By
repeated measures analysis of all time points, p 5 0.032 for the difference
in change in left ventricular end-diastolic volume index between the
treatment groups.
Figure 2. Mean change from baseline (with 95% confidence interval) in left
ventricular end-systolic volume index in the two treatment groups. By
repeated measures analysis of all time points, p 5 0.006 for the difference
in change in left ventricular end-diastolic volume index between the
treatment groups.
Figure 3. Mean change from baseline (with 95% confidence interval) in left
ventricular ejection fraction in the two treatment groups. By repeated
measures analysis of all time points, p 5 0.15 for the difference in change
in left ventricular end-diastolic volume index between the treatment
groups.
Table 3. Clinical Outcome by Treatment Group Among










At 3 months 0/0 0/0
At 12 months 1/0 4/3
End of study 1/0 4/3 .0.20*
Cardiac death, AMI or heart failure
At 3 months 0 3
At 12 months 3 6
End of study 5 13 0.046*
*By the log-rank test.
AMI 5 acute myocardial infarction.
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on the baseline electrocardiogram, triple-vessel disease and
CABG versus PTCA were not significantly associated with
the outcome. In the multivariate regression model control-
ling for assignment to ramipril and WMI ,1.4, the
univariate predictors, with few exceptions, remained as the
independent predictors (Table 5). Increases in EDVI and
ESVI from baseline to three months and a significant
increase in ESVI or a decrease in LVEF up to 12 months
were independent predictors of an increasing risk of a future
adverse outcome (Table 5, right columns). Similar results
were obtained when age, hypertension, diabetes mellitus
and gender were forced into the multivariate model or when
LVEF #0.40 was determined by ventriculography or echo-
cardiography.
The multivariate model also revealed that when the
change from baseline in EDVI, ESVI and LVEF were
added as predictors, assignment to ramipril was no longer an
independent predictor (Table 5). This points to a link
between the beneficial effect of ramipril on LV volumes and
LVEF and the beneficial effect of ramipril on clinical
outcome.
Cardiac death. The number of patients who had a cardiac
death and who had sequential echocardiograms was too low
(n 5 3) to allow for detailed statistical analysis. However,
the available data suggest an excellent survival rate for
patients without significant LV dilation up to three months.
The frequency of cardiac death for patients who did not
have a significant increase in EDVI up to three months was
1 (0.9%) in 111 (95% CI 0% to 2.7%), and the frequency for
patients without a significant increase in ESVI up to three
months was 1 (0.9%) in 107 (95% CI 0% to 2.7%). For
patients who had a significant increase in EDVI and ESVI
up to three months, the frequencies were 2 (10%) in 20
(95% CI 23.1% to 23.1%) and 2 (8.3%) in 24 (95% CI
22.7% to 19.3%), respectively.
DISCUSSION
Left ventricular volumes and LVEF are important prognos-
tic predictors for patients with AMI (9,17) and for patients
undergoing invasive revascularization (1–3). After AMI,
subsequent LV dilation and a decrease in LVEF can further
identify patients at high risk (9,18); this patient group, in
particular, seems to benefit from attenuation of LV dilation
by treatment with ACE inhibitors (9). In contrast, the
clinical significance of changes in LV volume and LVEF after
invasive revascularization and that of drug treatments that
might further modify these measures have not been clarified.
The main findings in this study are that: 1) ramipril
reduced LV end-diastolic and end-systolic volumes, as
compared with placebo; 2) postoperative increases in EDVI
and ESVI were associated with an increasing risk of
sustaining the triple composite end point of cardiac death,
AMI or development of clinical heart failure; 3) the level of
increase in EDVI and ESVI from baseline up to three
months postoperatively provided independent, predictive
information with respect to future clinical outcome; and 4)
there was an association between the effect of ramipril on
EDVI and ESVI and the clinical benefit with ramipril.
Comparisons and dissimilarities with other studies. It is
well documented that ACE inhibitor treatment, as com-
pared with placebo, reduces LV volume in patients with
AMI and LV dysfunction (8,9,12). The effect of LV
remodeling after AMI seems most explicit in the first
months(s) after AMI (8,12); therefore, it might be ques-
tionable whether the effect of ACE inhibitors on LV
Table 4. Predictive Information of Changes From Baseline Left Ventricular End-Diastolic Volume, End-Systolic Volume and
Ejection Fraction in Univariate Regression Model for Triple Composite End Point of Cardiac Death, Acute Myocardial Infarction
or Development of Heart Failure
All Patients
Patients Free of Triple Composite
End Point at 3 Months (n 5 128)
and 12 Months (n 5 118)
RR 95% CI p Value RR 95% CI p Value
DEDVI at 3 months 2.12 1.29–3.50 0.003 2.11 1.22–3.63 0.007
Significant DEDVI at 3 months 4.09 1.58–10.56 0.004 3.30 1.13–9.67 0.030
DESVI at 3 months 2.24 1.32–3.80 0.003 2.25 1.26–4.02 0.006
Significant DESVI at 3 months 2.75 1.01–7.43 0.047 2.00 0.67–6.7 0.23
DLVEF at 3 months 1.12 0.64–1.95 0.692 1.20 0.64–2.27 0.565
Significant DLVEF at 3 months 1.25 0.29–5.44 0.769 1.51 0.34–6.67 0.587
DEDVI at 12 months 1.58 0.99–2.52 0.057 1.32 0.73–2.38 0.357
Significant DEDVI at 12 months 2.80 1.05–7.50 0.040 1.40 0.35–5.65 0.637
DESVI at 12 months 2.32 1.33–4.04 0.003 1.91 0.97–3.76 0.062
Significant DESVI at 12 months 7.07 2.55–19.59 , 0.001 5.68 1.51–21.41 0.010
DLVEF at 12 months 1.40 0.89–2.19 0.144 1.20 0.68–2.13 0.525
Significant DLVEF at 12 months 3.83 1.33–11.02 0.013 6.80 1.82–25.39 0.004
Patients were categorized and assigned a rank (1 to 4) according to quartiles of DEDVI and DESVI and DLVEF, and relative risk was calculated according to one step in rank
(i.e., for increases in EDVI and ESVI and for decreases in LVEF). The right columns (patients free of end point at 3 months and 12 months, respectively) indicate risk of future
event.
CI 5 confidence interval; DEDVI, DESVI and DLVEF 5 increases from baseline in end-diastolic volume index, end-systolic volume index and left ventricular ejection
fraction, respectively; RR 5 relative risk; significant DEDVI, DESVI and DLVEF 5 increases in EDVI and ESVI or decrease in LVEF greater than the repeatability coefficient,
respectively.
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volume applies to patients without AMI. However, results
from the Studies Of Left Ventricular Dysfunction
(SOLVD) show that it may (10,11), at least in patients with
more severe LV dysfunction. In the present study, the
patients had no AMI and had less LV systolic dysfunction
as compared with the patients in the large ACE inhibitor
trials (9–11). Nevertheless, we found an effect of ramipril on
LV volume.
Although some previous studies may have suggested an
effect of ACE inhibitors on LV volume in patients with
lesser degrees of systolic dysfunction (8,12), our findings are
novel in that: 1) our patients had no recent AMI; 2) they
had just undergone invasive revascularization, an interven-
tion that may improve outcome and alter LV function and
dimensions; and 3) we were able to demonstrate a clinical
importance of the effect of ramipril on LV volume. Thus,
our results indicate that the beneficial effect of ACE
inhibitor treatment on LV volume extends beyond patients
with AMI, severe LV dysfunction or clinical heart failure
and may add to the benefit of invasive revascularization.
Support of this finding may be found in recent studies of
patients with chronic atherosclerotic disease and no severe
LV dysfunction or heart failure. Thus, in the Prevention of
Atherosclerosis with Ramipril Trial (19), ramipril reduced
the end-diastolic dimension and cardiovascular death, and
in the Heart Outcomes Prevention Evaluation (HOPE)
study (20), ramipril, in addition to reducing cardiovascular
death, prevented development of heart failure.
Compared with patients with a first AMI, the patients in
the present study may, due to the long duration of ischemic
heart disease and a process of late remodeling, at a given
ejection fraction, have more right-shifted and steeper parts of
volume-pressure loops. A further increase in LV volume may
then be more prone to produce symptoms in these patients.
This notion may be supported by the findings of Hamer et al.
(3) of the relative importance of LV volume as compared with
LVEF for the prognosis for patients without a recent myocar-
dial infarction undergoing invasive revascularization.
Similar to previous studies (8,10–12), the effect of ACE
inhibitor treatment on LV volume seems most explicit in
the early months after initiation of therapy. Thereafter, the
rate of change apparently parallels between the treatment
groups. Since we did not perform a withdrawal study, it
remains unsettled whether the impact of ramipril on LV
volume represents a “true” remodeling or a “resetting” of the
LV. The strong prognostic significance of the changes in
EDVI and ESVI from baseline up to three months is
nevertheless indicative of the importance of unloading the
LV soon after invasive revascularization in the present
patient group.
Comparisons with main study. The baseline characteris-
tics and the effect of ramipril on the triple composite end
point were comparable with the findings in the main study.
However, fewer patients who had a cardiac death were
included in this echocardiographic study as compared with
the main study. Therefore, this echocardiographic study
Table 5. Predictive Information of Changes From Baseline in Left Ventricular End-Diastolic Volume, End-Systolic Volume and
Ejection Fraction in Multivariate Regression Model for Triple Composite End Point of Cardiac Death, Acute Myocardial Infarction
or Development of Heart Failure
All Patients
Patients Free of Triple Composite
End Point at 3 Months (n 5 128)
and 12 Months (n 5 118)
RR 95% CI p Value RR 95% CI p Value
DEDVI at 3 months 1.87 1.14–3.07 0.013 1.91 1.11–3.27 0.019
WMI ,1.4 2.80 1.08–7.30 0.035 2.76 0.97–7.83 0.057
Ramipril assignment 0.47 0.16–1.34 0.156 0.60 0.20–1.80 0.363
Significant DEDVI at 3 months 3.00 1.09–8.23 0.033 2.61 0.84–8.17 0.098
WMI ,1.4 2.82 1.08–7.39 0.035 2.88 1.01–8.21 0.047
Ramipril assignment 0.47 0.16–1.39 0.172 0.57 0.18–1.78 0.335
DESVI at 3 months 2.03 1.18–3.48 0.010 2.09 1.16–3.75 0.014
WMI ,1.4 2.83 1.09–7.36 0.033 2.81 0.99–7.97 0.052
Ramipril assignment 0.50 0.18–1.43 0.199 0.65 0.22–1.94 0.443
Significant DESVI at 3 months 1.97 0.71–5.49 0.196 1.52 0.46–4.98 0.492
WMI ,1.4 2.80 1.06–7.41 0.038 2.91 1.01–8.37 0.048
Ramipril assignment 0.38 0.13–1.08 0.070 0.47 0.16–1.40 0.177
DESVI at 12 months 1.81 1.03–3.16 0.038 1.65 0.79–3.45 0.185
WMI ,1.4 3.14 1.03–9.54 0.044 1.25 0.30–5.19 0.762
Ramipril assignment 0.60 0.20–1.77 0.351 0.36 0.07–1.81 0.216
Significant DESVI at 12 months 4.41 1.43–13.66 0.010 4.66 1.02–21.38 0.048
WMI ,1.4 2.65 0.85–8.26 0.092 0.93 0.21–4.07 0.920
Ramipril assignment 0.63 0.21–1.91 0.416 0.40 0.08–2.02 0.266
Significant DLVEF at 12 months 3.56 1.19–10.64 0.023 5.45 1.39–21.47 0.015
WMI ,1.4 4.62 1.60–13.31 0.005 1.77 0.47–6.63 0.394
Ramipril assignment 0.50 0.17–1.48 0.213 0.39 0.08–2.00 0.260
Among the baseline variables, assignment to ramipril (relative risk [RR] 0.35, 95% confidence interval [CI] 0.12 to 0.98) and wall motion index (WMI) ,1.4 (RR 3.23, 95%
CI 1.25 to 8.38) were the single independent predictors at multivariate analysis. WMI 5 1.4 for the study group median; WMI ,1.4; ;LVEF #0.40.
For other abbreviations, refer to Table 4 footnote.
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may have had a bias toward demonstrating the mechanisms
behind preventing heart failure in preference to cardiac
death. Thus, the findings in the present study do not exclude
a possible role for the potential effects of ACE inhibitor
treatment on plaque vulnerability, the fibrinolytic system and
neurohormonal modulation (21) in the prevention of cardiac
and sudden death found in the main study (13).
Study limitations. The fact that the baseline measures of
EDVI, ESVI and LVEF were obtained before CABG but
after PTCA, as well as the possible altered position and
systolic motion of the heart after CABG, may limit the
comparison between baseline and postoperative measures.
However, first the study primarily aimed to compare the
difference in the treatment response between the ramipril
and placebo groups and the clinical significance thereof. It is
not likely that the aforementioned conditions should have
influenced systematically different in the two treatment
groups. Second, the significance of the difference in the
treatment response in EDVI and ESVI between the
ramipril and placebo groups was consistent when PTCA
versus CABG was added as a covariate. Finally, the prog-
nostic importance of the measured changes from baseline in
LV volume and LVEF suggests that the measured changes
actually may reflect “true” changes.
A concern may be raised about the lower LVEF derived
from EDVI and ESVI, as compared with LVEF obtained at
ventriculography or from WMI. However, according to the
design of the study (analyzing echocardiograms from sepa-
rate occasions side by side and blinded to the recording
sequence) and the statistical analyses used, the study pa-
tients served as their own control subjects. Thereby, the
echocardiographic outcome measures were more dependent
on precision than on accuracy. The reproducibility analysis
and the association between our echocardiographic outcome
measures and the patients’ clinical outcomes suggest that
our precision was adequate for achieving the study goals.
Conclusions. Despite the clinical benefit of invasive revas-
cularization in patients with moderate LV dysfunction and
chronic stable angina pectoris, LV dilation may supervene
and lead to an adverse outcome. Treatment with ramipril
reduces the postoperative increase in LV volumes, and this
effect is associated with a reduction in future cardiac events.
This finding may partly explain the outcome in APRES
(13). Thus, it appears that the benefit of LV unloading with
ACE inhibitor treatment may be extended to apply to
patients with only moderately impaired LV function and no
clinical heart failure undergoing invasive revascularization
for chronic angina pectoris.
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